Showing results (281-290 of 322) with videos related to

Sort By:
Pageof 33
Nature Biomedical Engineering|June 22, 2021
A prototype closed-loop brain-machine interface for the study and treatment of painQiaosheng Zhang, Sile Hu, Robert Talay, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2019
(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actionsPanos Zanos, Jaclyn N Highland, Brent W Stewart, et al.
The Lancet. Psychiatry|August 25, 2023
Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studiesGustavo C Medeiros, Malcolm Matheson, Isabella Demo, et al.
Scientific Reports|June 16, 2018
Response inhibition on the stop signal task improves during cardiac contractionCharlotte L Rae, Vanessa E Botan, Cassandra D Gould van Praag, et al.
Frontiers in Psychiatry|May 2, 2022
The Effect of the 5-HT4 Agonist, Prucalopride, on a Functional Magnetic Resonance Imaging Faces Task in the Healthy Human BrainAngharad N de Cates, Marieke A G Martens, Lucy C Wright, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 8, 2020
Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depressionCristan A Farmer, Jessica R Gilbert, Ruin Moaddel, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 7, 2020
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depressionCristan A Farmer, Jessica R Gilbert, Ruin Moaddel, et al.
British Journal of Pharmacology|April 4, 2019
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic dosesPanos Zanos, Jaclyn N Highland, Xin Liu, et al.
ACS Chemical Neuroscience|February 3, 2022
Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketaminesJaclyn N Highland, Patrick J Morris, Kylie M Konrath, et al.
Pharmacological Reviews|March 6, 2021
Hydroxynorketamines: Pharmacology and Potential Therapeutic ApplicationsJaclyn N Highland, Panos Zanos, Lace M Riggs, et al.
Pageof 33